Takeda has dropped another celiac…
Takeda has dropped another celiac disease therapy from its phase [...]
Sanofi’s new CEO Belén Garijo…
Sanofi’s new CEO Belén Garijo opened up for the first [...]
Johnson & Johnson is cruising…
Johnson & Johnson is cruising deeper into in vivo CAR-T [...]
A panel of experts today voted…
A panel of experts today voted against Capricor’s cell therapy [...]
AbCellera’s T-cell engager…
AbCellera’s T-cell engager platform has reeled in a second client [...]
Flush with GLP-1 cash and pipeline…
Flush with GLP-1 cash and pipeline success, Eli Lilly rose [...]
Incyte has ditched a JAK2…
Incyte has ditched a JAK2 inhibitor in phase 1 development [...]
Hansoh Pharmaceutical has guided…
Hansoh Pharmaceutical has guided its GSK-partnered, B7-H3-directed antibody-drug conjugate to [...]
A new biotech has come into view…
A new biotech has come into view with a $118 [...]
Rare disease biotech Oak Hill is…
Rare disease biotech Oak Hill is headed to the Nasdaq [...]